Table 1.
Clinical data of 38 HIV-infected subjects with less than 200 cells/mm3 of CD4+ T cells
| No. | Sex | Age (years) | Follow-up (years) | CD4+ T (cells/mm3) | CD8+ T (cells/mm3) | Viral load* (Log10 RNA) | Therapy | Duration of antiretroviral treatment† (years) |
|---|---|---|---|---|---|---|---|---|
| 1 | M | 44 | 11·8 | 175 | 623 | 4·1 | None | |
| 2 | M | 56 | 9·9 | 75 | 1737 | 5·8 | AZT | 5·4 |
| 3 | M | 31 | 10·3 | 174 | 520 | 4·4 | None | |
| 4 | M | 57 | 9·7 | 164 | 929 | 4·6 | None | |
| 5 | M | 39 | 10·3 | 172 | 882 | 4·9 | AZT, IDV | 6·8 |
| 6 | M | 68 | 8·7 | 93 | 368 | 4·6 | None | |
| 7 | M | 50 | 15·8 | 110 | 1900 | Neg. | AZT, 3TC, IDV | 3·5 |
| 8 | M | 24 | 9·3 | 131 | 803 | 4·6 | None | |
| 9 | M | 39 | 7·4 | 196 | 593 | 4·7 | AZT | 4·9 |
| 10 | M | 43 | 6·6 | 64 | 990 | Neg. | AZT, 3TC, IDV | 3·9 |
| 11 | M | 71 | 7·1 | 116 | 1065 | 4·0 | None | |
| 12 | M | 32 | 6·6 | 56 | 326 | 5·2 | None | |
| 13 | M | 34 | 5·8 | 117 | 1076 | 4·6 | None | |
| 14 | M | 53 | 6·3 | 147 | 1384 | 4·3 | AZT | 5·2 |
| 15 | F | 28 | 5·5 | 125 | 463 | NA | None | |
| 16 | F | 29 | 5·4 | 186 | 573 | NA | None | |
| 17 | M | 50 | 4·9 | 172 | 934 | NA | None | |
| 18 | M | 42 | 4·6 | 77 | 1575 | 5·1 | None | |
| 19 | M | 36 | 4·4 | 71 | 369 | Neg. | AZT | 2·0 |
| 20 | M | 39 | 4·5 | 85 | 703 | 6·1 | AZT, 3TC, IDV | 3·4 |
| 21 | F | 21 | 1·5 | 155 | 406 | 4·5 | None | |
| 22 | F | 63 | 1·8 | 125 | 541 | 4·3 | None | |
| 23 | M | 51 | 1·6 | 58 | 221 | 4·8 | None | |
| 24 | F | 44 | 2·3 | 128 | 802 | 3·8 | AZT, 3TC, IDV | 1·3 |
| 25 | M | 22 | 0·9 | 102 | 199 | 5·4 | None | |
| 26 | F | 53 | 3·4 | 81 | 504 | 4·7 | None | |
| 27 | M | 51 | 8·9 | 95 | 919 | 5·0 | AZT, 3TC | 0·1 |
| 28 | F | 57 | 4·1 | 181 | 1316 | 6·0 | None | |
| 29 | M | 24 | 1·8 | 130 | 1124 | NA | None | |
| 30 | F | 21 | 1·4 | 186 | 703 | 4·1 | None | |
| 31 | M | 23 | 0·9 | 195 | 841 | 4·2 | None | |
| 32 | F | 33 | 4·6 | 34 | 543 | 4·9 | None | |
| 33 | F | 28 | 5·3 | 1 | 79 | 6·2 | 3TC, Nelfinavir | 0·3 |
| 34 | M | 44 | 6·0 | 36 | 185 | 4·9 | AZT | 1·1 |
| 35 | M | 51 | 2·0 | 8 | 841 | 4·3 | AZT, 3TC, IDV | 1·9 |
| 36 | M | 40 | 4·1 | 31 | 966 | 4·2 | AZT | 0·4 |
| 37 | M | 52 | 3·3 | 43 | 497 | 4·9 | None | |
| 38 | M | 42 | 0·1 | 9 | 164 | 6·2 | None |
*
Viral load: Log10 HIV-1 RNA; limit of detection: 400 copies/ml, Neg. Negative, NA: Not available.
†
Therapy: reverse transcriptase inhibitors: AZT (Zidovudine), 3TC (Lamivudine); protease inhibitors: IDV (Indinavir), Nelfinavir.
‡
Sum of the duration of individual’s antiretroviral treatment. Even though an individual had either mono-, combination treatment or cocktail treatment, the number represents only the sum of the duration of all treatments.